Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
FDMT — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

22.86

Margin Of Safety %

Put/Call OI Ratio

0.52

EPS Next Q Diff

-1.42

EPS Last/This Y

-1.39

EPS This/Next Y

0.01

Price

10.26

Target Price

29.38

Analyst Recom

1.5

Performance Q

40.27

Upside

-418.7%

Beta

3.03

Ticker: FDMT




16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09FDMT8.740.230.003240
2026-03-10FDMT8.870.230.083243
2026-03-11FDMT8.540.230.153255
2026-03-12FDMT8.470.232.863245
2026-03-13FDMT8.450.232.863245
2026-03-17FDMT8.60.2487.313303
2026-03-18FDMT8.570.66999.994433
2026-03-20FDMT8.630.771.674526
2026-03-25FDMT9.890.580.574421
2026-03-26FDMT10.190.590.244431
2026-03-27FDMT9.330.600.024473
2026-03-30FDMT8.570.587.134568
2026-03-31FDMT9.320.580.014572
2026-04-01FDMT9.870.560.014669
2026-04-06FDMT9.950.560.004659
2026-04-07FDMT10.250.520.004912
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09FDMT8.7241.3- -3.26
2026-03-10FDMT8.8641.3- -3.26
2026-03-11FDMT8.5341.3- -3.26
2026-03-12FDMT8.4641.3- -3.26
2026-03-13FDMT8.3541.3- -3.26
2026-03-17FDMT8.6141.3- -3.26
2026-03-18FDMT8.5641.3- -3.26
2026-03-19FDMT8.9941.3- -3.26
2026-03-20FDMT8.6141.3- -3.26
2026-03-23FDMT9.2341.3- -3.26
2026-03-24FDMT9.1941.3- -3.26
2026-03-25FDMT9.8941.3- -3.26
2026-03-26FDMT10.1941.3- -3.26
2026-03-27FDMT9.3241.3- -3.26
2026-03-30FDMT8.57-17.3- -3.75
2026-03-31FDMT9.31-17.3- -3.75
2026-04-01FDMT9.86-17.3- -3.75
2026-04-02FDMT9.47-17.3- -3.75
2026-04-06FDMT9.96-16.7- -3.81
2026-04-07FDMT10.26-16.7- -3.81
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09FDMT-0.2330.1421.38
2026-03-10FDMT-0.2330.1421.38
2026-03-11FDMT-0.2330.1422.29
2026-03-12FDMT-0.2330.1422.29
2026-03-13FDMT-0.2330.1422.29
2026-03-18FDMT-0.2330.0122.29
2026-03-19FDMT-0.2330.0122.29
2026-03-20FDMT-0.2330.0122.29
2026-03-23FDMT-0.2334.9722.27
2026-03-24FDMT-0.2334.9722.27
2026-03-25FDMT-0.2434.9722.86
2026-03-26FDMT-0.2434.9722.86
2026-03-27FDMT-0.1934.9722.86
2026-03-30FDMT-0.1930.0422.86
2026-03-31FDMT-0.1930.0422.86
2026-04-01FDMT-0.1930.0422.86
2026-04-02FDMT-0.1930.0422.86
2026-04-06FDMT-0.1930.0422.86
2026-04-07FDMT-0.1930.0422.86
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.43

Avg. EPS Est. Current Quarter

-1.01

Avg. EPS Est. Next Quarter

-0.99

Insider Transactions

-0.19

Institutional Transactions

30.04

Beta

3.03

Average Sales Estimate Current Quarter

3

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

23

Growth Score

53

Sentiment Score

63

Actual DrawDown %

76.2

Max Drawdown 5-Year %

-94.1

Target Price

29.38

P/E

Forward P/E

PEG

P/S

6.14

P/B

1.17

P/Free Cash Flow

EPS

-2.51

Average EPS Est. Cur. Y​

-3.81

EPS Next Y. (Est.)

-3.8

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-164.43

Relative Volume

1.35

Return on Equity vs Sector %

-55.2

Return on Equity vs Industry %

-38.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.33

EBIT Estimation

FDMT Healthcare
$10.24
📉
Swing / Pullback
Buy the dip on strong trends
47 /100
WEAK
Trend
20/20
Pullback
6/25
Volume
3/15
Valuation
9/20
TP/AR
2/10
Options
7/10
RSI
59.4
Range 1M
82.3%
Sup Dist
5.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
43 /100
WEAK
Momentum
12/25
Growth
14/30
Estimates
1/20
Inst/Vol
11/15
Options
5/10
EPS Yr
-58.1%
EPS NY
-0.8%
52W%
79%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +186.9% upside
Quality
6/30
Valuation
16/30
Growth
8/25
Stability
9/10
LT Trend
4/5
Upside
+186.9%
Quality
23
4D Molecular Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 196
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
FDMT

Latest News

Caricamento notizie per FDMT
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading